MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a privately held company specializing in the discovery and development of oncology therapeutics, announced today that, effective immediately, Dr. Andrew Pecora, FACP, has joined the Company’s Board of Directors, bringing the Board to seven members.
